Literature DB >> 11309361

Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines.

S S Lakka1, R Rajagopal, M K Rajan, P M Mohan, Y Adachi, D H Dinh, W C Olivero, M Gujrati, F Ali-Osman, J A Roth, W K Yung, A P Kyritsis, J S Rao.   

Abstract

The urokinase-type plasminogen activator (uPA) and its receptor (uPAR) play an important role in the proteolytic cascade involved in the metastasis of lung and other cancers. We report that the reduction in uPAR levels produced by an antisense strategy using an adenovirus construct (Ad-uPAR) in H1299 cells, an invasive human lung cancer cell line that produces high levels of uPAR, resulted in a decrease of uPAR levels to 80-90% of those seen in cells infected with mock or adenovirus (Ad)-cytomegalovirus vector controls. In addition, increasing the multiplicity of infection from 25 to 200 caused a corresponding decrease in the level of uPAR protein within 5 days of treatment, as shown by Western blot analysis. Furthermore, the in vitro translation of total RNA levels of Ad-uPAR-infected H1299 cells in a rabbit reticulocyte lysate system caused a 50-70% decrease in uPAR immunoprecipitate in Ad-uPAR-infected cells relative to the levels in cells of mock and vector controls. The Matrigel invasion assay showed the invasion of H1299 cells and A549 cells infected with Ad-uPAR to be decreased by 70% relative to mock- and vector-infected controls. Infection of tumor cells with Ad-uPAR before implantation significantly reduced the incidence of lung metastasis by 85% as compared with the control virus-infected cells injected into nude mice through the tail vein. Our collective results show that the uPAR system is a potential target of treatment for lung cancers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11309361

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

1.  Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.

Authors:  Sai Duriseti; David H Goetz; Daniel R Hostetter; Aaron M LeBeau; Ying Wei; Charles S Craik
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

2.  Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma.

Authors:  Crispin R Dass; Anne P W Nadesapillai; Daniel Robin; Monique L Howard; Jane L Fisher; Hong Zhou; Peter F M Choong
Journal:  Clin Exp Metastasis       Date:  2006-04-29       Impact factor: 5.150

3.  Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells.

Authors:  Jasti S Rao; Christopher Gondi; Chandramu Chetty; Subramanyam Chittivelu; Pushpa A Joseph; Sajani S Lakka
Journal:  Mol Cancer Ther       Date:  2005-09       Impact factor: 6.261

4.  Decreased TIP30 expression promotes tumor metastasis in lung cancer.

Authors:  Xin Tong; Kai Li; Zhigang Luo; Bin Lu; Xing Liu; Tao Wang; Mingshu Pang; Beibei Liang; Min Tan; Mengchao Wu; Jian Zhao; Yajun Guo
Journal:  Am J Pathol       Date:  2009-04-06       Impact factor: 4.307

5.  Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.

Authors:  Chi-Hui Tang; Marla L Hill; Alexis N Brumwell; Harold A Chapman; Ying Wei
Journal:  J Cell Sci       Date:  2008-10-21       Impact factor: 5.285

6.  uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo.

Authors:  Odysseas Kargiotis; Chandramu Chetty; Venkateswara Gogineni; Christopher S Gondi; Sai Muralikrishna Pulukuri; Athanassios P Kyritsis; Meena Gujrati; Jeffrey D Klopfenstein; Dzung H Dinh; Jasti S Rao
Journal:  Int J Oncol       Date:  2008-11       Impact factor: 5.650

7.  Evaluating the value of uPAR of serum and tissue on patients with cervical cancer.

Authors:  Jiexian Jing; Shumin Zheng; Cunzhi Han; Lili Du; Yongfeng Guo; Pei Wang
Journal:  J Clin Lab Anal       Date:  2012-01       Impact factor: 2.352

Review 8.  Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases.

Authors:  Christopher S Gondi; Jasti S Rao
Journal:  Methods Mol Biol       Date:  2009

9.  Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer.

Authors:  Nunzia Montuori; Ada Pesapane; Francesca W Rossi; Valentina Giudice; Amato De Paulis; Carmine Selleri; Pia Ragno
Journal:  Transl Med UniSa       Date:  2016-11-01

10.  CRISPR/Cas9 nickase mediated targeting of urokinase receptor gene inhibits neuroblastoma cell proliferation.

Authors:  Karina D Rysenkova; Ekaterina V Semina; Maxim N Karagyaur; Anna A Shmakova; Daniyar T Dyikanov; Petr A Vasiluev; Yury P Rubtsov; Kseniya A Rubina; Vsevolod A Tkachuk
Journal:  Oncotarget       Date:  2018-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.